Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, ...

Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $41 from $46 and keeps an Outperform rating ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

The companies Insmed, Cidara Therapeutics, and Cogent Biosciences bagged the biggest biotech funding rounds overall in June ...

Dyne Therapeutics secures $275 million loan to advance treatments for myotonic dystrophy and Duchenne muscular dystrophy. Quiver AI Summary. Dyne Therapeutics, Inc. has announced a $275 million ...

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases ...

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically ...

Dyne Therapeutics, Inc. - FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - ...

The one-person biotech with operations in Cambridge plans to grow its presence in Kendall Square and abroad in Europe with a ...

Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ...

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases ...